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Abstract
To investigate the consequences of intermittent preventive treatment (IPTp) timing on birth weight, we pooled data from
two studies conducted in Benin between 2005 and 2010: a prospective cohort of 1037 pregnant women and a randomised
trial comparing sulfadoxine-pyrimethamine (SP) to mefloquine in 1601 women. A total of 1439 women (752 in the cohort
and 687 in the SP arm of the randomised trial) who delivered live singletons were analysed. We showed that an early intake
of the first SP dose (4 months of gestation) was associated with a lower risk of LBW compared to a late intake (6–7 months
of gestation) (aOR=0.5 p=0.01). We also found a borderline increased risk of placental infection when the first SP dose was
administered early in pregnancy (aOR=1.7 p=0.1). This study is the first to investigate the timing of SP administration
during pregnancy. We clearly demonstrated that women who had an early intake of the first SP dose were less at risk of LBW
compared to those who had a late intake. Pregnant women should be encouraged to attend antenatal visits early to get
their first SP dose and a third dose of SP could be recommended to cover the whole duration of pregnancy and to avoid late
infections of the placenta.
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Introduction
To prevent the consequences of malaria in pregnancy (MiP),
intermittent preventive treatment (IPTp) strategy has been
recommended since the early 2000s, and adopted by most African
countries (including Benin in 2004). It consists in the administra-
tion under supervision of 2 curative doses of sulfadoxine
pyrimethamine (SP) at least one month apart from the second
trimester of pregnancy.
In Benin, a prospective cohort of pregnant women (‘‘Strategy
TO Prevent Pregnancy Associated Malaria’’ (STOPPAM)) was
conducted from 2008 to 2010 to study immunological responses
against MiP. In a preceding paper [1], we have highlighted the
importance of the timing of malaria infections on the consequenc-
es of MiP. In early pregnancy, peripheral infections were
associated with a higher risk of maternal anaemia at delivery,
and with a decrease in the baby’s mean birth weight. At the end of
pregnancy, malaria infections increased the risk of maternal
anaemia at delivery, without altering birth weight significantly.
Hence the currently implemented schedule appears to leave the
beginning of pregnancy unprotected, and the coverage of late
pregnancy largely depends on the time of administration of the
two doses of SP [2].
Therefore, as stressed by the World Health Organisation [3],
there is a need to find an optimal timing for IPTp administration.
To investigate this issue, the results from STOPPAM were
compared, and then pooled with a randomised IPTp trial carried
out in Ouidah, a nearby area, from 2005 to 2008.
Materials and Methods
Ethics statement
The 2 studies were approved by the ethics committees of the
Research Institute for Development in France, and of the Science
and Health Faculty in Benin. Written informed consent was given
by all participants.
Study area
The 2 studies have already been described in detail elsewhere
[1,4]. Briefly, the two sites are located in South Benin, 20 km apart
from each other (figure 1). Ouidah area is semi-rural, whereas the
area of STOPPAM study is more rural. Malaria transmission is
high throughout the year, with two peaks from April to July and
September to November. In a survey performed in 2005, in vivo
resistance to SP was estimated at 50% in children under five in
Ouidah [5]. In women followed in the trial, the prevalence of pfdhfr
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,2gene triple mutants (codons 51, 59, and 108) and pfdhfr-pfdhps
quadruple mutants (pfdhfr codons 51, 59, and 108 and pfdhps codon
437) before first SP administration was 81% and 74%, respectively
[6]. In STOPPAM study, the mutation prevalence remained
stable over pregnancy with 85% quadruple and no quintuple
mutants. (Tuikue Ndam, personal communication).
Ouidah randomised trial
In Ouidah (40 km west from Cotonou), the controlled trial was
conducted in 3 maternity clinics: Kindji, Kpasse ´ and Hopital de
Zone comparing SP (1,500–75 mg per dose) versus mefloquine
(15 mg/kg per dose) for IPTp. Women under 28 weeks of
gestation were included in the study. The first dose was scheduled
between 16 and 28 weeks, and the second after 30 weeks of
gestation, with at least 1 month in between. The two intakes were
strictly supervised. Before each intake, a thick blood smear (TBS)
was made. In case of clinical symptoms, women were encouraged
to attend the clinic. At delivery, birth weight was measured and
TBS, placental smears and blood samples were collected. The
gestational age was assessed using the Ballard score [7], and
performed by a single trained midwife within 72 hours after birth.
STOPPAM study
In Come ´ area, a prospective cohort of pregnant women was
followed in 3 maternity clinics: Come ´ central, Ouedeme Pedah
and Akodeha. Women under 24 weeks of gestation were included
in the study. Two doses of SP IPTp were administered following
the national guidelines. Women were followed-up monthly from
inclusion to delivery at the clinics. Like in Ouidah, women were
encouraged to consult in case of symptoms. The gestational age
was accurately estimated either by a midwife trained for
ultrasound or by an obstetrician. On each visit (antenatal visit
(ANV) or unscheduled visit), a rapid diagnostic test and a TBS
were performed. At delivery, newborns were weighed. A TBS and
placental smears were made and blood samples were drawn.
Laboratory procedures
Placental smears from the two studies were stained with
Giemsa. Malaria parasites were counted against 200 leukocytes.
To ensure the quality of the smear reading, a control with a double
reading was performed in both studies.
Statistical analysis
Stata version 11 for Windows (Stata Corp, College Station, TX,
USA) was used for all statistical analyses.
Outcome definitions. A birth weight under 2,500 g was
considered as low birth weight. Placental infection was considered
positive on the basis of the placental smears.
-Comparison of the 2 studies. To ensure comparability, we
analyzed women only in the SP arm of the Ouidah trial. HIV
infected women who received 3 doses of SP were excluded from
the analysis. Only women with available dates for the two SP
Figure 1. Study area of the randomized trial in Ouidah and STOPPAM.
doi:10.1371/journal.pone.0035342.g001
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analysis. We compared the baseline characteristics of the women,
outcomes, and the timing of SP intakes between the 2 studies.
Different outcomes were considered: LBW, birth weight, and
placental infection. Differences in proportions and means were
compared using the chi2 test (or Fisher’s exact test) and the
Student t-test, respectively.
Influence of the timing of SP administration on
outcomes. In order to find the best timing for SP
administration, we pooled the data from the 2 studies and
performed a logistic or a linear regression depending on the
outcome analyzed (binary or continuous).
We used 2 variables to account for the position and the duration
of IPTp throughout the pregnancy for each woman. First, we
defined a variable measuring the date of administration of first SP
dose according to the gestational age estimated by the Ballard
score or by ultrasound, depending on the study. It was categorised
in 3 classes: 4 completed months of gestation (14 weeks of gestation
and 6 days - 19 weeks), 5 months (19 weeks and 1 day- 23 weeks
and 3 days), and 6–7 months of gestation (23 weeks and 4 days - 32
weeks). Then, we created a variable measuring the interval
between the 2 SP intakes and transformed it into a four class
variable corresponding to the quartiles.
Covariates were included in the initial models on the basis of the
literature and on hypothesized underlying causal relationships
(directed acyclic graphs (DAG)) [8,9]. We considered the following
covariates: sex of the newborn, parity (primigravidae or multi-
gravidae), possession of bed net, education, mother’s underweight
(body mass index(BMI),20 before pregnancy calculated by
assuming a weight gain of 250 g per week of pregnancy), number
of consultations (total number of ANVs and unscheduled visits,
dichotomised: under or above the median), duration of pregnancy
(3 classes: #38 weeks, 39 weeks and $40 weeks of gestation).
To evaluate the influence of the women’s exposure to malaria,
we created a four-level variable. The different levels correspond to
the 4 possible SP administration patterns regarding the transmis-
sion periods: 2 doses during rainy season or dry season, first dose
during rainy season and second during dry season, and first dose
during dry season and second during rainy season. In the analysis,
this variable was considered mainly as an indicator of both the
time position and duration of the transmission period in the course
of pregnancy. For instance, women who received 2 SP doses
during the rainy season probably had a longer duration of
pregnancy during the transmission period (and therefore had a
longest duration to malaria exposure) compared to women who
took 2 SP doses during dry season.
We identified each study (Ouidah trial or STOPPAM) as a
covariate and included it in the initial model. Covariates were
selected using a backward-stepwise strategy to obtain the final
multivariable model, a p-value of ,0.05 was considered
statistically significant.
Results
Comparison of the 2 studies
In the Ouidah trial, 1,601 women were randomised: 802 in the
mefloquine group and 799 in the SP group. In the SP arm, 733
women had 2 intakes of SP (4 were HIV infected; 62 received only
one dose). Among them, we analyzed the data of 687 women with
live singletons (10 sets of twins, 13 stillbirths, 1 miscarriage and 22
newborns with unavailable birth weights).
In the STOPPAM study, 982 women were followed-up and 845
had 2 intakes of SP (121 received a single dose or date of SP intake
was unknown, 16 were HIV infected). After excluding 1
miscarriage, 27 stillbirths, 4 maternal deaths, 19 sets of twins
and 42 newborns whose birth weight was unknown, 752 women
and their live singletons were kept for analysis.
Finally, a total of 1,439 women and their live singletons were
analyzed.
Table 1 presents the general characteristics of the mothers and
the outcomes of the 2 studies.
In the STOPPAM study, there were more primigravidae than
in Ouidah (26.4% vs 18.2%), while the women were older on
average (26.4 years vs 24.9). More women received no education
in the STOPPAM study (56.5% vs 44.7%). In both studies,
women were from close ethnic groups of South West Benin. More
women declared they owned a bed net at enrolment in the Ouidah
trial than in the STOPPAM study (69.6% vs 31.9%, p,0.001).
There were more women in the STOPPAM study who attended
more than the median 5 visits during their follow-up (78.9% vs
43.7%; p,0.001).
The first dose of IPTp was given later in the Ouidah trial than
in the STOPPAM study (159.6 days (standard deviation
(SD)=23.3) (22 weeks and 5 days of gestation) vs 144.7
(SD=21.5) (20 weeks and 4 days of gestation); p,0.001). The
interval between the 2 doses was longer in Ouidah compared to
the STOPPAM study (60.3 (SD=23.1) vs 35.4 days (SD=9.9)
p,0.001). The mean birth weight and proportion of LBW were
3,008.2 g (SD=474.1) and 10.6% in the STOPPAM study and
3,037.1 g (SD=429.6) and 8.6% in the Ouidah trial, respectively.
Neither mean birth weight nor LBW differed significantly between
the 2 studies. Among the 1439 analyzed women, information on
placental infection was missing for 178 women. However, age,
education, use of bed net, proportion of underweight women were
the same in women with available outcomes and those without
(data not shown). The proportion of placental infection was higher
in the STOPPAM study than in the Ouidah controlled trial
(11.3% vs 4.1%; p,0.001).
Influence of SP timing on birth weight and placental
infection
After pooling the two studies, multivariable logistic regression
showed that LBW was associated with a 0.5 decreased risk
(p=0.01) when the first dose was given early during pregnancy (4
months of gestation), compared to a late intake (6–7 months of
gestation). There was no relation between the risk of LBW and the
interval between doses. The risk of LBW was significantly higher
for primigravidae and low-BMI women than for multigravidae
and normal-BMI (aOR=2.4; p,0.001 and aOR=1.7; p=0.009,
respectively). The administration of 2 SP doses during the dry
season versus rainy season resulted in a lower risk of LBW. As
expected, women with a shorter duration of pregnancy had an
increased risk of LBW (table 2).
A first SP dose administered at the fourth or fifth month of
gestation was associated to an increase in mean birth weight
(138.2 g, p,0.001, and 72.5 g; p=0.008, respectively) compared
to a late intake (6–7 months of gestation). Similarly to LBW, no
association was observed between the time between SP doses and
birth weight. Mean birth weight was higher in the Ouidah trial
than in the STOPPAM study (an increase of 63.1 g; p=0.04).
Having received 2 SP doses during the dry season resulted in an
increase of mean birth weight (73.1 g; p=0.02) compared to 2
doses during the rainy season. Low BMI, first pregnancy, foetal
gender, low number of consultations and short duration of
pregnancy were also associated with a decrease in mean birth
weight (table 3).
Although not significant, we observed a marginal increase in the
risk of placental infection with an early first SP dose (aOR=1.7;
Intermittent Preventive Treatment Timing
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interval between doses was observed. Mothers from the Ouidah
trial had a reduced risk for a placental infection (aOR=0.4;
p=0.005) and primigravidae presented with a greater risk of
placental infection (aOR=2.6; p,0.001) (table 4).
Discussion
We investigated the importance of the timing of SP IPTp by
analysing 2 follow-ups of women throughout pregnancy in Benin.
We showed that the moment of administration of the first dose of
SP had a significant influence on birth weight. An early intake of
the first SP dose was associated with a lower risk of LBW
compared to a late intake (a reduction by half) and with an
increase in mean birth weight (more than 100 g). These findings
are consistent with what we found in a preceding paper [1] and
with the results of Cottrell et al. [10]. These studies showed that
malaria infections during early pregnancy (,19 weeks) were
particularly harmful for the mother and the newborn.
The timing of SP administration was only marginally associated
with placental infection. The fact that the rate of placental
infection was lower in the Ouidah trial than in the STOPPAM
study may be explained by a later administration of the second SP
dose, as the infection of the placenta at delivery probably reflects a
late peripheral infection. An alternative explanation involves a
better compliance due to the strict supervision of SP administra-
tion according to the directly observed therapy scheme in the
randomised trial.
The timing of IPTp thus seems to act differently on LBW and
placental infection. Foetal growth is maximal from the middle of
the second trimester until the last month of pregnancy [11],
therefore an early intake of SP may clear placental infections
before the maximal growth velocity, allowing the foetus to grow
harmoniously. On the contrary, a late intake susceptible to clear
the placenta at delivery, may not improve in the same extent the
foetal growth. A recent review highlighted different mechanisms
by which malaria infections could lead to foetal growth restriction
and therefore LBW [12]. Two periods appear to be crucial. Early
infections may alter the angiogenesis causing placental insufficien-
cy, whereas later infections may contribute to placental dysfunc-
tion through inflammation of the syncytiotrophoblast, decreasing
nutrient transport or causing hormone dysregulation. Conse-
quently, an early IPTp intake, by allowing a correct process of
Table 1. General characteristics of the women and outcomes of the 2 studies.
Ouidah trial STOPPAM p value*
Number of women 687 752
Mean age, (years)# 24.9 (5.5; 15–45) 26.4 (SD=6.1, range=15–45) ,0.001
Parity n (%) Primigravidae 181 (18.2) 137 (26.4)
Multigravidae 506 (81.8) 615 (73.6) ,0.001
Education n (%) No education 307 (44.7) 425 (56.5)
Partial or complete primary 259 (37.7) 212 (28.2) ,0.001
Secondary 121 (17.6) 115 (15.3)
Weight before pregnancy n (%) BMI{$20 491 (72.1) 474 (63.8)
BMI,20 190 (27.9) 269 (36.2) 0.001
Bed net at enrollment n (%) No 209 (30.4) 511 (68.1)
Yes 478 (69.6) 239 (31.9) ,0.001
Total number of visits n (%) $5 visits 300 (43.7) 593 (78.9)
,5 visits 387 (56.3) 159 (21.1) ,0.001
Newborn sex n (%) Male 349 (50.9) 387 (51.5)
Female 336 (49.1) 365 (48.5) 0.85
Low birth weight n (%) No 628 (91.4) 672 (89.4)
Yes 59 (8.6) 80 (10.6) 0.19
Mean weight at delivery (g)# 3037.1 (429.6; 1350–4434) 3008.23 (SD=474.1; range=1250–
4850)
0.23
Placental infection n (%) No 583 (95.9) 579 (88.7)
Yes 25 (4.1) 74 (11.3) ,0.001
Interval time between the last
menstruation period and the first intake,
days (SD)
159.6 (23.3) 144.7 (21.5) ,0.001
First SP dose intake timing n (%) 6–7 months of gestation 287 (41.8) 120 (15.9)
5 months of gestation 277 (40.3) 357 (47.5)
4 months of gestation 123 (17.9) 275 (36.6)
Interval time between the 2 doses, days
(SD)
60.3 (23.1) 35.4 (9.9) ,0.001
#mean, (Standard deviation (SD); range).
*Differences between the 2 studies in proportions and means were compared using the x
2 and the Student t-test, respectively.
{Body mass index.
doi:10.1371/journal.pone.0035342.t001
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infection, which occurs later in the course of pregnancy.
Although the ideal way to evaluate the best time to start IPTp is
a randomized trial comparing different timings, raising appropri-
ate funding for such a trial, not involving new antimalarial drugs,
would not be easy. In Benin, two investigations on pregnant
women receiving SP-IPTp were available, thus offering a unique
opportunity to answer this question without building up a
complete trial. In the STOPPAM study, women were encouraged
to attend ANVs early, and they were offered ultrasound for the
assessment of gestational age, which may have motivated them for
early attendance at the clinic. No such facilities were proposed in
the Ouidah trial, hence on average the first ANV was performed
later than in STOPPAM.
The women differed regarding the study they originated from.
STOPPAM women were older and had a lower school attendance
compared to those from Ouidah. There were also more
underweight individuals and primigravidae in STOPPAM,
probably because of the more rural setting of this study. Getting
free of charge follow-up, STOPPAM women’s attendance to visits
was higher, but they were less likely to possess an insecticide-
treated net at inclusion than in Ouidah. However, the two studies
were close to each other in terms of space and time. In both
studies, the same type of population (pregnant women) was
followed, under comparable transmission conditions and the same
prevention strategy against MiP (SP IPTp). Finally, because we
adjusted for all possible confounding factors in the different
statistical models, it seems unlikely that pooling the two datasets
could have led us to seriously biased results.
We could also verify the usual associations of known risk factors,
such as a shorter duration of pregnancy, foetal sex, and maternal
underweight with LBW, in agreement with previous studies on
MiP [13,14]. We assume that the finding of a lower rate of LBW
associated with the intake of 2 SP doses during the dry season,
compared to the rainy season, reflects the deleterious effect of the
transmission season (and the associated increase in exposure to
mosquito infective bites during rainy season) on pregnancy
outcomes, rather than a higher efficacy of IPTp in this particular
period.
Finally, we compared baseline characteristics of the women,
such as education level or nutritional status assessed by the BMI,
with the gestational age at enrolment, to rule out a potential
selection bias (data not shown). We did not evidence any difference
in the nutritional status, while a higher level of education was
found in women who enrolled late in pregnancy ($4 months,
compared with ,4 months), thus confirming the relation between
the timing of IPTp and low birth weight.
It is noticeable that in the analyses of the factors associated with
mean birth weight or placental infection, the Ouidah trial was
associated to an overall higher protection than the STOPPAM
study, even considering the later administration of IPTp in the
former. In Ouidah trial, SP was administered under direct
supervision whereas the supervision was looser in the STOPPAM
study. These results are consistent with the findings of another
study in a nearby site, Tori Bossito [15], where IPTp was given by
the national health system. In this study, rates of placental
infection and LBW were quasi-identical to those found in
STOPPAM. The high degree of protection achieved by the
Table 2. Factors significantly associated with low birth weight (Multivariate analysis performed on 1439 women and adjusted on
newborn’s gender, study, number of consultations, bed net and education).
Adjusted OR* 95% Confidence interval p value
First dose intake 6–7 months of gestation 1
5 months of gestation 0.8 [0.5, 1.3] 0.46
4 months of gestation 0.5 [0.3, 0.9] 0.01
Interval time between the 2
doses
#31 days 1
32–37 days 0.9 [0.5, 1.5] 0.65
38–61 days 0.7 [0.4, 1.3] 0.3
.62 days 1.0 [0.6, 1.9] 0.8
Parity Multigravidae 1
Primigravidae 2.4 [1.6, 3.6] ,0.001
Underweight BMI{$20 1
BMI,20 1.7 [1.1, 2.5] 0.009
Duration of pregnancy $40 weeks of gestation 1
39 weeks of gestation 2.0 [1.1, 3.7] 0.02
#38 weeks of gestation 10.7 [6.2, 18.5] ,0.001
Transmission period Dose 1 and dose 2 during rainy season 1
Dose 1 during rainy season and dose 2 during
dry season
0.8 [0.4,1.5] 0.50
Dose 1 during dry season and dose 2 during
rainy season
0.8 [0.4,1.4] 0.4
Dose 1 and dose 2 during dry season 0.6 [0.3,0.9] 0.05
*OR, odds ratio;
{Body mass index.
doi:10.1371/journal.pone.0035342.t002
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bed net, education).
Adjusted difference
in mean birth weight (g) 95% Confidence interval p
First dose intake 6–7 months of gestation 0
5 months of gestation 72.5 [18.7, 126.4] 0.008
4 months of gestation 138.2 [75.25 200.9] ,0.001
Interval time between the 2 doses #31 days 0
32–37 days 12.0 [247.0, 71.1] 0.69
38–61 days 3.2 [259.8, 66.3] 0.98
.62 days 233.1 [2107.9, 41.7] 0.36
Parity Multigravidae 0
Primigravidae 2179.7 [2230.6, 2128.8] ,0.001
Study STOPPAM 0
Ouidah trial 63.1 [1.6, 124.6] 0.04
Underweight BMI*$20 0
BMI,20 2132.5 [2178.0, 287.0] ,0.001
Duration of pregnancy $40 weeks of gestation 0
39 weeks of gestation 2147.9 [2196.8, 299.0] ,0.001
#38 weeks of gestation 2422.4 [2477.3, 2367.5] ,0.001
Newborn’s gender Male 0
Female 2100.4 [2142.1, 258.7] ,0.001
Number of consultations $5 consultations 0
,5 consultations 266.1 [2110.0, 222.1] 0.03
Transmission period Dose 1 and dose 2 during rainy season 0
Dose 1 during rainy season and dose 2
during dry season
26.5 [243.9, 96.9] 0.46
Dose 1 during dry season and dose 2
during rainy season
44.3 [225.9, 114.5] 0.22
Dose 1 and dose 2 during dry season 73.1 [10.6, 135.6] 0.02
*Body mass index.
doi:10.1371/journal.pone.0035342.t003
Table 4. Factors significantly associated with placental infection (Multivariate analysis performed on 1261 women and adjusted on
newborn’s gender, number of consultations, bed net, underweight, education, duration of pregnancy and transmission period).
Adjusted OR* 95% Confidence interval p value
First dose intake 6–7 months of gestation 1
5 months of gestation 1.2 [0.6, 2.1] 0.6
4 months of gestation 1.7 [0.9, 3.1] 0.1
Interval time between the 2 doses #31 days 1
32–37 days 1.0 [0.6, 1.8] 0.84
38–61 days 1.4 [0.8, 2.5] 0.26
.62 days 0.7 [0.3, 1.7] 0.43
Parity Multigravidae 1
Primigravidae 2.6 [1.6, 4.1] ,0.001
Study STOPPAM 1
Ouidah trial 0.4 [0.2, 0.8] 0.005
*OR, odds ratio.
doi:10.1371/journal.pone.0035342.t004
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the directly observed therapy scheme.
The estimation of gestational age differed in the 2 studies,
Ballard score in Ouidah and ultrasound scan in STOPPAM. In
the Ouidah trial, all Ballard scores were measured exclusively by
one specifically trained midwife to avoid inter-operator variability.
All postnatal examinations were made within 72 hours (at a
median time of 14 hours). In the STOPPAM study, ultrasound
scan was precociously performed by only 2 operators. Therefore,
the assessment of gestational age was made carefully in both
studies and could not lead to biases. Moreover, we made the same
analysis for each study separately, and found significant results for
the different outcomes (data not shown). By combining the 2
studies, we confirmed the results while increasing the power of the
analysis.
SP IPTp has already demonstrated its efficacy in West Africa
[16,17,18,19] as well as in East Africa [20,21], in reducing the risk
of LBW. By delivering the first SP dose earlier during the second
trimester of pregnancy, we observed a gain of 100 g in mean birth
weight, which is an important step comparable to the improve-
ment (110 to 170 g) previously achieved by the shift from
prophylaxis, either SP or chloroquine, to IPTp [16,22]. Women
should then be encouraged to attend antenatal visits early, as soon
as they feel the quickening (15–20 weeks of gestation) to get their
first dose of SP. This measure should not disrupt existing
guidelines and minor efforts, regarding the considered benefit,
will be required for a successful change.
A possible drawback of an early intake of SP IPTp is the lower
protection during late pregnancy. Indeed, in the STOPPAM
study, two thirds of the infected symptomatic women during
unscheduled visits were found in late pregnancy, after the sixth
month. [23]. Similar observations were made in Ouidah (V.
Briand, personal communication): women were seen at unsched-
uled symptomatic visits between 6 and 8 weeks after IPTp intake
on average. From a pathophysiological point of view, a recent
article [24] suggested that using SP for IPTp could induce a
competitive facilitation of the most highly resistant parasites,
responsible for higher levels of parasitaemia and possibly more
acute symptoms. To avoid such an inconvenience, a third dose
should be considered at the end of pregnancy. A few studies have
investigated the efficacy of more than 2 SP doses in HIV negative
women, suggesting a better efficacy of these schemes [25,26],
providing a better coverage of pregnancy as well as a better
efficacy to overcome increasing resistance [3]. A very recently
published randomised trial in Mali [27] has shown the superiority
of a three-dose over two-dose SP IPTp on both placental infection
and LBW. In sub-Saharan Africa, the attendance to ANVs is high:
70% of the women attend at least once and among them, 95%
attend twice and more than half attend 4 times [11]. The World
Health Organisation recommends 4 ANVs including 3 after
quickening for a good pregnancy surveillance through the
‘‘focused antenatal care’’. A 3 dose-IPTp after the quickening
could then be entirely part of the focused antenatal care strategy.
In conclusion, our study is to our knowledge the first to
investigate the timing of SP administration during pregnancy. The
results clearly show that women who had an early intake of the
first dose of SP were less at risk of LBW compared to those with a
later intake. In the context of increasing resistance to SP,
researches are focusing on the finding of new candidates to
replace SP for IPTp, if possible safe during the first trimester of
pregnancy. It is of the utmost importance to ensure that future
trials take into account the timing of the administration of drugs,
and particularly an early intake and the full coverage of the
pregnancy period.
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